NCT07431853

A Study to Learn About mRNA Vaccines Against Influenza in Adults

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MRNA VACCINES AGAINST INFLUENZA IN ADULTS 18 YEARS OF AGE AND OLDER

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 770 (estimated)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to learn about safety in participants taking the study vaccine (mRNA-based vaccine) and the ability of the study vaccine to trigger the body's immune response, targeting the flu virus (influenza virus). This study is seeking healthy participants 18 years of age or older. All participants in this study will receive only 1 dose in their arm, to deliver one of the experimental flu vaccines or one of the approved flu vaccines used for comparison. Participants will take part in this study for about 6 months, and participants will need to visit the study site at least 3 times. A blood sample will be taken at each of the 3 planned study visits and a swab from inside the nose will be taken at the first study visit.

Conditions

• Healthy Adults

Interventions

Type	Name	Description
BIOLOGICAL	Vaccine Candidate #1	Investigational influenza Vaccine
BIOLOGICAL	Vaccine Candidate #2	Investigational influenza Vaccine
BIOLOGICAL	Vaccine Candidate #3	Investigational Influenza Vaccine
BIOLOGICAL	Vaccine Candidate #4	Investigational Influenza Vaccine
BIOLOGICAL	Vaccine Candidate #5	Investigational Influenza Vaccine
BIOLOGICAL	Vaccine Candidate #6	Investigational Influenza Vaccine
BIOLOGICAL	TIV1 or TIV2	Licensed influenza vaccine

Timeline

• Start date: 2026-02-23
• Primary completion: 2027-06-22
• Completion: 2027-06-22
• First posted: 2026-02-25
• Last updated: 2026-03-20

Locations

15 sites across 1 country: United States

Regulatory

• FDA-regulated drug study